Introduction
Nearly 90 % of neoplastic polyps usually removed during colonoscopy are small and
diminutive [1]. With such a high proportion, it is crucial to find a safe and effective way to
resect the lesions to optimize procedural safety, effectiveness, and efficiency. Hot
snare polypectomy (HSP) has been applied as the conventional procedure for removing
lesions by means of electrocautery. Use of electrocautery, however, may lead to thermal
injury of the colonic wall and increase risk of subsequent delayed bleeding, post-polypectomy
syndrome and even perforation [2]. Therefore, the authors of prior studies have speculated that these procedure-related
risks could be reduced by replacing conventional electrocautery with a more effective
polypectomy method [3]
[4].
Cold snare polypectomy (CSP) is a method for removing small and diminutive polyps
by mechanical transection with polypectomy snare without applying electrocautery.
This technique was first introduced in 1985 by Tappero et al., who removed 288 consecutive
small polyps using mechanical strangulation [3]. In their series, no bleeding, perforation or mortality occurred. As such, CSP was
considered to have potential to reduce risk of post-polypectomy bleeding attributable
to thermal injury. Thus, the European Society of Gastrointestinal Endoscopy clinical
guideline recommended CSP for removing diminutive and small polyps [5]. A recent retrospective case-control study also supported that CSP could effectively
reduce the risk of post-polypectomy bleeding [6]. The superiority of CSP in reducing bleeding complications was also explored in
high-risk subjects. Horiuchi et al. demonstrated in a randomized controlled trial
(RCT) that risk of post-polypectomy bleeding of subjects taking anticoagulants could
be reduced by CSP [4]. However, one meta-analysis that summarized six RCTs demonstrated that CSP and HSP
had a comparable risk of post-polypectomy bleeding [7]. Nevertheless, RCTs investigating the efficacy of CSP in reducing risk of post-polypectomy
bleeding in an average-risk screening population are lacking because to show the paucity
of bleeding events with sufficient statistical power requires a large sample size
[8]
[9]
[10]
[11]
[12]. Even with the evidence to date of multiple studies, it remains inconclusive whether
CSP is able to reduce risk of post-polypectomy bleeding and further investigation
is warranted.
We hypothesized that implementation of CSP practice in an endoscopic unit may significantly
reduce risk of post-polypectomy bleeding. Therefore, the aim of this study was to
compare risk of bleeding in a high-volume screening colonoscopy setting before and
after universal implementation of CSP for resecting polyps of less than 10 mm.
Patients and methods
Study sample, setting, implementation of CSP, and ethical considerations
Study subjects were selected from a consecutive series of patients who voluntarily
submitted to annual health check-ups, including screening colonoscopy, at the Health
Management Center of National Taiwan University Hospital. The annual volume of this
screening unit is more than 8000 patients. Detected colorectal polyps are routinely
removed by forceps biopsy, snare polypectomy, or endoscopic mucosal resection (EMR)
as indicated. Patients who receive screening colonoscopy are routinely contacted by
telephone after the procedure to monitor and ascertain the occurrence of any adverse
events within 48 hours. In addition, a 24-hour hotline is also provided for the convenience
of contact by the participants. Any significant post-colonoscopy adverse events, including
bleeding, post-polypectomy syndrome, even perforation and emergency department visits,
are routinely recorded in the administrative database. Every patient could be reached
by this bidirectional telephone contact and this can guarantee the completeness of
follow-up and minimize the possibility of response bias.
CSP was implemented in March 2016 and colorectal polyps measuring 4 to 10 mm were
removed by CSP thereafter. Prior to implementation of CSP, HSP was the standard way
of removing polyps measuring 4 to 10 mm during colonoscopy. Except for switching from
HSP to CSP, application of forceps biopsy for removing tiny polyps or snare polypectomy/EMR
for larger polyps was not changed. Accordingly, the duration of March 2016 to August
2017 was defined as the CSP period and January 2015 to March 2016 as the HSP period
as an historical control. Either CSP or HSP was the only modality for removing polyps
sized 4 to 10 mm in individual corresponding period.
The comorbid status was measured and quantified with Charlson comorbidity index (CCI),
which is a well-documented and comprehensive method for scoring comorbidity [13]. Before implementation of the current study, the study protocol received approval
(No.201802040RIND) from the institutional review board and the ethical committee of
our institution. The study report manuscript was prepared according to the guidelines
provided by the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) Statement [14].
Endoscopic procedures and perioperative management
Prior to screening colonoscopy, all participants were asked to complete and submit
a standard questionnaire to obtain their personal and medical history, including use
of antiplatelet or anticoagulant agents, existence of comorbidities, and indications
for colonoscopy as described in our previous study [15]. The laxative regimen and timing of bowel preparation in our setting was also addressed
as previously described [16]. The regimen for bowel preparation was same-day 2-liter polypethylene glycol electrolyte
lavage solution (PEG-ELS) following by 1- to 2-liter water at the timing of 5 to 9
hours prior to colonoscopy. During colonoscopy withdrawal, the detected polyp(s) was
documented in terms of anatomical location, size, and methods applied for neoplasm
resection. Lesion size was measured using biopsy forceps with a 2-mm outer diameter
or snares with an outer diameter of 10 to 20 mm. Polyp morphology was classified according
to the Paris classification [17]. Lesions smaller than 4 mm were removed by cold forceps biopsy in both groups. Lesions
larger than 10 mm were removed by either endoscopic mucosal resection (EMR) (flat
or sessile lesions) or HSP (pedunculated lesions) during both CSP and HSP periods.
For lesions measuring 4 to 10 mm, CSP was applied routinely after its March 1 implementation.
The procedures were performed by seven experienced colonoscopists from our institution
using a colonoscope with variable-stiffness function (CF-260 or 290 series; Olympus
Medical Systems, Tokyo, Japan). All colonoscopists had sufficient expertise and skills
for performing polypectomy, together representing at least 5000 previous colonoscopies.
Each endoscopist had at least 7 years of experience before the beginning of the study
and it ensure the steady performance before and after implementation of CSP. Stiff
snares were used for CSP (Captivator-Small Hex 13 mm, Captivator II-Round 10 mm, and
Captivator II-Round 15 mm, Boston Scientific, Massachusetts, United States). For each
procedure, one of these snares was applied based on the size and morphology of the
lesions and preference of the colonoscopists. Either HSP or CSP was performed by the
same group of colonoscopists during the two periods. The same types of snares were
applied for HSP and CSP.
Main outcome measures
The major outcome measure in this study was delayed post-polypectomy bleeding before
and after implementation of CSP. Bleeding severity was graded as spontaneous stop,
need for second-look colonoscopy, and severe bleeding. Bleeding with spontaneous stop
was defined as bloody stool stopped spontaneously without the need for any medical
or surgical intervention. Need for second-look colonoscopy was defined as bleeding
needing second-look colonoscopy but did not require hemostasis procedure. Severe bleeding
was defined as active bleeding that required colonoscopic hemostasis, involved a hemoglobin
drop of 2 g/dL or more as compared with baseline, or required blood transfusion. Emergency
services (ES) visits and hospitalization were also recorded. Both CSP and HSP were
performed during colonoscope withdrawal and total procedure time was recorded and
compared. The hospital stay for each study subject was defined as the average summation
of the procedure time, ES stay time, and hospitalization time.
Histological diagnosis
Colorectal polyps, including conventional adenomas and serrated lesions, were classified
according to World Health Organization (WHO) criteria [18]. Lesion location was defined by anatomic distribution. Proximal location was defined
as the colon above the splenic flexure and the remaining part of the colon, from the
descending colon to the rectum, was defined as the distal colon.
Statistical analysis
Student t-test was used for comparison of continuous variables including age, gender, body
mass index (BMI), CCI, tumor size, polyp number, procedure time and hospital stay.
Pearson X
2 test was used for comparison of categorical variables, such as bleeding risk, ES
visit, hospitalization, tissue retrieval rate and use of medications.
Logistic regression analysis was used to estimate risk of post-polypectomy bleeding
and odds ratios (ORs) with 95 % confidence intervals (CI) were calculated. Univariate
analysis was used to evaluate variables such as age, gender, tumor size, number of
polyps, polypectomy method, anatomical location, bowel cleansing level, BMI and CCI.
Those variables with a P value < 0.1 in univariate analysis were entered into multivariate analysis. In multivariate
analysis, P values < 0.05 were considered statistically significant. Statistical analysis was
performed using SPSS statistical package, version 17.0 (IBM Corp, Armonk, New York,
United States).
Results
Patient demographic and clinical characteristics
A total of 16,873 subjects received screening colonoscopy during the whole study period
(January 2015 to August 2017). Of these, 9,804 colonoscopies were performed and 1,304
subjects received polypectomy prior to implementation of CSP. After implementation
of CSP, 7,069 colonoscopies were performed and 1,255 subjects received polypectomy
([Fig. 1]).
Fig. 1 Diagram showing the two study cohorts, implementation of CSP and bleeding events.
Study subjects’ demographic and clinical characteristics population are shown in [Table 1]. No significant differences were found between the two cohorts in proportion of
subjects using antiplatelet or anticoagulant agents and comorbidity status. Clinical
information on the colorectal polyps resected during both time periods is shown in
[Table 2]. A total of 1,822 and 1,850 colorectal polyps were removed in CSP and HSP periods,
respectively. Anatomical distribution (proximally located: 61.8 % vs. 60.3 %, P = 0.34) and mean lesion size (7.42 ± 5.72 vs. 7.65 ± 5.23, P = 0.19) were similar between the two cohorts. The tissue retrieval rate was also
similar (CSP vs. HSP = 98.0 % vs. 98.7 %, P = 0.11)
Table 1
Demographic and clinical characteristics of the study cohorts.
|
CSP cohort N = 1,255
|
HSP cohort N = 1,304
|
P value
|
|
Age, years ± SD
|
58.84 ± 11.63
|
57.86 ± 11.73
|
0.04
|
|
Male, n (%)
|
780 (62.1)
|
811 (62.2)
|
0.98
|
|
Subject with more than 3 polyps, n (%)
|
117 (9.3)
|
125 (9.6)
|
0.82
|
|
Use of antiplatelet or anticoagulant agents, n (%)
|
75 (6.0)
|
84 (6.4)
|
0.63
|
|
BMI, kg/m2 ± SD
|
24.48 ± 3.39
|
24.43 ± 3.56
|
0.74
|
|
Charlson comorbidity index
|
0.11 ± 0.48
|
0.13 ± 0.45
|
0.37
|
CSP, cold snare polypectomy; HSP, hot snare polypectomy; BMI, body mass index; SD,
standard deviation
Table 2
Clinical data on colorectal polyps.
|
CSP N = 1,822
|
HSP N = 1,850
|
P value
|
|
Proximal location, n (%)
|
1126 (61.8)
|
1115 (60.3)
|
0.34
|
|
Resected lesion, n (%)
|
|
HP
|
202 (11.0)
|
259 (14.0)
|
|
|
SSA/P
|
207 (11.3)
|
237 (12.8)
|
|
TA
|
1128 (61.6)
|
1047 (56.5)
|
|
TVA
|
242 (13.2)
|
278 (15.0)
|
|
HGD
|
6 (0.3)
|
4 (0.2)
|
|
Unknown
|
37 (2.0)
|
25 (1.4)
|
|
Tissue retrieval rate, n (%)
|
1785 (98.0)
|
1825 (98.7)
|
0.11
|
|
Tumor size, mm ± SD
|
7.42 ± 5.72
|
7.65 ± 5.23
|
0.19
|
CSP, cold snare polypectomy; HSP, hot snare polypectomy, HP: hyperplastic polyp; SSA/P,
sessile serrated polyp/adenoma; TA, tubular adenoma; TVA, tubulovillous adenoma; HGD,
high-grade dysplasia; SD, standard deviation
Adverse events and procedure times for CSP and HSP
Only one delayed post-polypectomy bleeding event occurred during the CSP period, which
subsided spontaneously and required neither intervention nor blood transfusion. During
the HSP period, a total of 14 subjects experienced delayed post-colonoscopy bleeding.
All delayed bleeding events occurred between the first and eighth day after polypectomy,
with a mean of 2.79 ± 2.01 days. Among those patients, 11 subjects required second-look
colonoscopy, nine had severe bleeding, and two were hospitalized. The CSP cohort had
significantly lower rates of bleeding (P < 0.001), need for second-look colonoscopy (P < 0.01), severe bleeding (P < 0.01), and ES visits (P < 0.01) compared with the HSP cohort. Mean procedure time, 12.60 ± 11.45 vs. 16.48 ± 14.27 min/person, and mean hospital stay, 1.18 ± 0.50 vs. 1.53 ± 5.78 hour/person,
were both significantly shorter in the CSP period than in the HSP period (P values < 0.01 and 0.03, respectively) ([Table 3]).
Table 3
Comparison of adverse events and procedure times for CSP vs. HSP.
|
CSP N = 1,255
|
HSP N = 1,304
|
P value
|
|
Bleeding, n (%)
|
1 (0.1)
|
14 (1.1)
|
< .001
|
|
|
1 (0.1)
|
3 (0.2)
|
0.34
|
|
|
0 (0.0)
|
11 (0.8)
|
< .01
|
|
|
0 (0.0)
|
9 (0.7)
|
< .01
|
|
ES visit, n (%)
|
1 (0.1)
|
13 (1.0)
|
< .01
|
|
Hospitalization, n (%)
|
0 (0.0)
|
2 (0.2)
|
0.17
|
|
Total procedure time, min/person ± SD
|
12.60 ± 11.45
|
16.48 ± 14.27
|
< . 01
|
|
Hospital stay, hour/person ± SD[2]
|
1.18 ± 0.50
|
1.53 ± 5.78
|
0.03
|
CSP, cold snare polypectomy; HSP, hot snare polypectomy; ES, emergency services; SD,
standard deviation
1 Severe bleeding: hemostasis by colonoscopy; hemoglobin dropped by 2 gm/dL in comparison
with baseline; or require blood transfusion.
2 Hospital stay was defined as the average summation of the procedure time, ES stay
time, and hospitalization time for each person.
Analyses of the risk factors associated with delayed post-polypectomy bleeding
Univariate analysis revealed that HSP was associated with significantly higher delayed
post-polypectomy bleeding (OR = 13.6, 95 % CI = 1.79 – 103.65). Number of polyps per
patient was marginally associated with risk of bleeding (OR = 1.22, 95 %CI = 0.98 – 1.52).
Tumor size (OR = 2.20, 95 %CI = 0.78 – 6.22), anatomical location (proximal vs. distal,
OR = 1.32, 95 %CI = 0.44 – 3.93), bowel cleansing level (adequate vs. inadequate, OR = 0.84, 95 %CI = 0.30 – 2.37), BMI (low vs. high, OR = 0.90, 95 %CI = 0.75 – 1.10) and CCI (low vs. high, OR = 0.70, 95 %CI = 0.15 – 3.31)
were not associated with risk of bleeding. In multivariate analysis, HSP remained
an independent significant risk factor for delayed post-polypectomy bleeding after
adjustment for age (aOR = 0.99, 95 %CI = 0.95 – 1.04), male gender (aOR = 0.58, 95 %CI = 0.18 – 1.83)
and number of polyps (aOR = 1.26, 95 %CI = 0.99 – 1.59) ([Table 4]).
Table 4
Risk of post-polypectomy bleeding associated with polypectomy method and other factors.
|
Univariate analysis
|
Multivariate analysis
|
|
OR (95 %CI)
|
P value
|
aOR (95 %CI)
|
P value
|
|
Age
|
0.99 (0.95 – 1.03)
|
0.64
|
0.99 (0.95 – 1.04)
|
0.73
|
|
Gender
|
0.60 (0.19 – 1.88)
|
0.38
|
0.58 (0.18 – 1.83)
|
0.35
|
|
Tumor size, ≥ 10 mm vs. < 10 mm
|
2.20 (0.78 – 6.22)
|
0.13
|
–
|
–
|
|
Number of polyps per patient
|
1.22 (0.98 – 1.52)
|
0.07
|
1.26 (0.99 – 1.59)
|
0.06
|
|
HSP vs. CSP
|
13.6 (1.79 – 103.7)
|
0.01
|
14.4 (1.88 – 110.6)
|
0.01
|
|
Anatomical location, Proximal vs. distal
|
1.32 (0.44 – 3.93)
|
0.62
|
–
|
–
|
|
Bowel cleansing level, adequate vs. inadequate
|
0.84 (0.30 – 2.37)
|
0.74
|
–
|
–
|
|
BMI (high vs. low)
|
0.90 (0.75 – 1.10)
|
0.26
|
–
|
–
|
|
Charlson comorbidity index (high vs. low)
|
0.70 (0.15 – 3.31)
|
0.65
|
–
|
–
|
aOR, adjusted odds ratio; HSP, hot snare polypectomy; CSP, cold snare polypectomy;
BMI, body mass index
Discussion
Results of the current study demonstrated that risk of delayed post-polypectomy bleeding,
need for second-look colonoscopy, frequency of ES visits and total procedure times
could be significantly reduced via implementation of CSP. The safety and efficiency
of polypectomy was significantly improved by implementation of CSP in the screening
colonoscopy setting.
Clinicians performing CSP speculated that it would be able to reduce risk of delayed
post-colonoscopy bleeding by avoiding thermal injury. Most of the direct evidence
to support this hypothesis has come from descriptive studies in which the adverse
events were investigated after CSP for consecutively enrolled subjects [3]
[19]. However, even though those studies demonstrated the superiority of CSP in reducing
delayed post-colonoscopy bleeding, most studies did not compare results with those
of HSP as a control. To the best of our knowledge, only one retrospective case-control
study compared these two methods. Yamashina et al. explored whether CSP could reduce
post-colonoscopy bleeding by comparing 330 and 209 subjects who received CSP and HSP,
respectively [6]. In the current study, a total of 2,559 of 16,873 subjects who received screening
colonoscopy and polypectomy in a large-volume screening colonoscopy setting were enrolled.
The sample size is larger than previous studies and it provides a more accurate demonstration
of the superiority of CSP over HSP in reducing risk of post-polypectomy bleeding.
Recent RCTs comparing CSP and HSP have failed to demonstrate the superiority of CSP
to reduce risk of post-colonoscopy bleeding except for the study by Horiuchi et al.
He explored the superiority of CSP in a high-risk population taking anticoagulant
agents, demonstrating that CSP could significantly lower risk of bleeding [4]. The actual risk of bleeding after removing small and diminutive polyps was very
low, ranging from 0 % to 1.3 %. Both the low risk and small sample may explain why
the pooled risk of bleeding in the meta-analysis was also non-significant. Designing
a large-scale RCT using the bleeding event as a primary outcome would be most ideal,
but long-term study is required. An alternative approach would be to explore such
risk in a screening setting involving a large patient population. The current study
enrolled 2,559 of 16,873 subjects participating in screening colonoscopy and such
a large sample size provides sufficient statistical power to demonstrate the superiority
of CSP. Not only colonoscopy experts but also general endoscopists performed the procedures
in our institute hence the results are more likely to reflect the real-world practice
setting rather than an experimental study involving only expert colonoscopists.
In several previous studies, bleeding was the most common adverse event after polypectomy,
occurring either immediately or days after the procedure, and the overall bleeding
rate after HSP was reported to range from 0.65 % to 0.87 % [20]
[21]
[22]. Because bleeding events increase medical costs and decrease patient satisfaction,
several screening programs have proposed a benchmark threshold for the rate of significant
bleeding events. Immediate bleeding was more common when electrocautery with cutting
or blended current was used, whereas delayed bleeding was more common when coagulation
current was used. Therefore, risk of delayed bleeding could be theoretically reduced
by avoiding electrocautery use [23]
[24]. A study by Repici et al. demonstrated that risk of delayed bleeding after CSP was
zero based on the observation of 823 patients. Although that study was only a single-arm
descriptive study without a control group, the advantage of CSP in the real-world
practice setting was well demonstrated [19]. In summary, a growing body of evidence supports the efficacy of CSP in reducing
post-polypectomy bleeding, including observational cohort studies and retrospective
case-control studies. Most of the RCTs to date have been either underpowered to evaluate
bleeding events owing either to a small sample size or a high-risk population, which
are not totally representative of the general screening population. Large-scale RCTs
with sufficient sample size enrolling a general screening population are still warranted.
Another advantage of CSP was saving procedural time, which may impact the efficiency
and cost-effectiveness of colonoscopy. Previous RCTs have demonstrated that CSP could
significantly save procedural time even though risk of bleeding was similar to HSP
[7]
[25] The current study demonstrated that CSP could significantly save total procedure
time compared with HSP and could save as much as 23.5 % procedure time per colonoscopy
that polypectomy was performed. Another significance of CSP is the completeness of
neoplasm eradication. Several RCTs have demonstrated that the complete eradication
rate using CSP was not only better than by cold forceps polypectomy [26]
[27], but also was not inferior to or even better than by HSP [25]. Another study reported a low rate of 0.98 % for pathologically verified residual
adenoma using CSP, which is an important indicator of efficacy [28]. Though not evaluated in the current study, the issue of histological eradication
had been well addressed in previous RCTs. Technical aspect was another issue worthwhile
to be discussed for CSP. Din et al. reported that the thickness and shape of the different
snares may have affected histological eradication rate of CSP [29]. Horiuchi et al. also noticed that a dedicated snare for CSP was able to achieve
more complete removal of the polyps [8]. Based on the results of that study, a shield-shaped and thin snare was considered
to be more suitable for complete removal of polyps. A thin snare provides more precise
cutting and the shield shape may facilitate proper positioning of the snare, both
contributing to better maneuverability in the CSP procedure. Further standardization
of the procedure is still necessary, including the technical details and optimal device
selection.
There were several strengths in the current study. First, the study was strengthened
by its large sample size. To the best of our knowledge, this was by far the largest
study population in which these two methods are compared. As such, it provides a sufficient
statistical power to test our hypothesis and allows comprehensive multivariate analysis
adjusting for potential confounders. Second, the short study period minimized the
influence of other factors, such as operator and endoscopic instrumental factors,
including the colonoscope, snare or electrosurgical unit. Operator members were completely
the same across two operative periods and so were the instruments used for colonoscopy.
Third, subjects who had concurrent polyp(s) larger than 10 mm were enrolled. For such
cases, small polyps were removed with either HSP or CSP as per the study period and
conventional methods, either HSP or EMR, were applied for resection of larger polyps
as indicated at the same endoscopic session. Such an approach is more likely to reflect
the real-world practice of screening colonoscopy. Finally, we also took into account
the comorbidity status of the study subjects, which may influence risk of post-polypectomy
bleeding. CCI, a comprehensive scoring system, was used to quantify comorbidity and
was taken into consideration in the regression analysis. This may provide a more precise
estimate of the effect of different polypectomy methods on bleeding risk.
Nevertheless, the current study was not without limitations. First, the retrospective
and non-randomized design, and therefore, the results, may be confounded by hidden
factors even though comprehensive multivariate analysis was conducted to adjust for
various confounders. Second, histological eradication rate was not re-assessed in
this study. Owing to the retrospective design, information on histologic eradication
was totally dependent on the initial pathology report thus interobserver variation
may exist. Nevertheless, such a histological issue has been well addressed in previous
RCTs for which histological eradication rate was primary endpoint. In this study,
bleeding event, rather than the histological eradication rate, was the main study
outcome. Third, one may argue that endoscopist experience might have changed over
time and affected the results. In this study, only experienced endoscopists were enrolled
and all of them performed colonoscopy for at least 7 years (ranged from 7 to 15 years),
hence significant differences in polypectomy performance before and after implementation
of CSP are less likely. Finally, although we observed significantly lower overall
procedural time using CSP, retrospective analysis did not allow us to specify and
compare the time spent on polypectomy itself. However, this is not likely to be an
issue, as the main difference in procedural time is more likely to be associated with
the different polypectomy methods rather than with scope insertion, withdrawal or
lesion observation, which were the same across the HSP and CSP periods.
Conclusion
In conclusion, CSP significantly reduces the risk of post-polypectomy bleeding and
overall procedural time compared with HSP for removing small and diminutive polyps
in a large screening colonoscopy setting. Further large-scale RCTs with a sufficient
sample from a screening population are still warranted to confirm results of the current
study and demonstrate the safety, efficacy and efficiency of CSP.